Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol?
CONCLUSION: Patients with nonatherosclerotic arterial occlusive disease also benefit from cilostazol, but patients with Buerger disease or diabetic angiopathy seem to benefit less. Combining cilostazol with anticoagulant or antiaggregant agents and closer monitoring of these patients may produce better results.PMID:36763036 | DOI:10.14503/THIJ-21-7747
Source: Texas Heart Institute Journal - Category: Cardiology Authors: Burak Can Depboylu Serkan Yazman Bugra Harmandar Muruvvet Funda Tetik Hande Istar Kadir Arslan Gokhan Ilhan Source Type: research
More News: Buerger's Disease | Cardiology | Cilostazol | Diabetes | Endocrinology | Heart | Intermittent Claudication | Statistics | Study | Thrombosis